arrow
L

Littisha Lawrance

guerbet research
H指数:8
被引数:195

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Liquid biopsy tumour fraction, total tumour volume, and automated whole-body CT body composition for survival stratification in metastatic cancer: a temporally validated pan-cancer cohort study

液体活检肿瘤分数、总肿瘤体积及自动化全身CT体成分分析在转移性癌症生存分层中的应用:一项经时间验证的泛癌种队列研究

2026-09-250
PRE
Integrating Tumor Volumetry and Liquid Biopsy: a New Model to Define Prognosis in Advanced Pancreatic Ductal Adenocarcinoma

整合肿瘤体积测量和液体活检:一种定义晚期胰腺导管腺癌预后的新模型

2026-05-010
PRE
The correlation of liquid biopsy genomic data to radiomics in colon, pancreatic, lung and prostatic cancer patients

液体活检基因组数据与结直肠癌、胰腺癌、肺癌和前列腺癌患者影像组学之间的相关性

2025-07-080
PRE
Baseline CT-derived tumor burden and liquid biopsy as biomarkers to predict survival in patients with metastatic solid cancer

基线CT测量的肿瘤负荷和液体活检作为预测转移性实体癌患者生存的生物标志物

2025-06-080
PRE
Subcutaneous fat mass predicts progression-free survival in patients treated with antibody-drug-conjugates in early-phase clinical trials
2024-03-220
PRE
Predicting overall survival of patients with melanoma and NSCLC treated with immunotherapy using AI combining total tumor volume and tumor heterogeneity on CT-Scans

使用AI结合ct扫描上的总肿瘤体积和肿瘤异质性预测接受免疫治疗的黑色素瘤和非小细胞肺癌患者的总体生存率

2023-10-010
OAAI
Synthetic MR image generation of macrotrabecular-massive hepatocellular carcinoma using generative adversarial networks

使用生成对抗网络生成大小梁-块状肝细胞癌的合成MR图像

2023-05-013
OAAI
Better than RECIST and Faster than iRECIST: Defining the Immunotherapy Progression Decision Score to Better Manage Progressive Tumors on Immunotherapy
2023-01-311
OA
An artificial intelligence model predicts the survival of solid tumour patients from imaging and clinical data
2022-10-018
PRE
Three artificial intelligence data challenges based on CT and ultrasound
2021-11-0113
OAAI